CGC-11047 + erlotinib

CGC-11047 + erlotinib is an investigational combination therapy studied primarily in oncology. CGC-11047 is a synthetic polyamine analogue developed to induce apoptosis in cancer cells, acting as an apoptosis stimulant. Erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), blocking its kinase activity and thereby inhibiting cell proliferation and survival signals in tumor cells. Erlotinib is approved for use as monotherapy or in combination with gemcitabine for non-small cell lung cancer (NSCLC) and pancreatic cancer, but the combination with CGC-11047 has been evaluated only in early-phase clinical trials to determine safety and dosing. The primary indication under investigation for this combination has been advanced solid tumors[2][3][7].

Brand names

Tarceva